EAAT2 has been implicated in the pathophysiology of several disorders of the CNS, including Parkinson’s disease, epilepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, addiction, schizophrenia, as well as MDD and BD.1 On the molecular level, there is strong evidence of downregulation of EAAT2 in diverse brain regions in MDD2,57. The gene discussed is SLC1A2; the disease is early-onset autosomal dominant Alzheimer disease.